Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | -5.45% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.29 | N/A | -5.45% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing research and development.
Management did not provide specific guidance for the upcoming quarters.
The company is focusing on its core research initiatives despite the financial results.
Tango Therapeutics I reported a wider-than-expected loss per share, which contributed to a significant drop in stock price. Investors reacted negatively, likely due to the lack of revenue information and guidance. The company's focus remains on its research initiatives, but the absence of specific future plans may raise concerns among investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
May 9, 2022